Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2011-10-05 14:23:48
Reporting Period:
Filing Date:
Accepted Time:
2011-10-05 14:23:48
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1301081 Pharmasset Inc VRUS Pharmaceutical Preparations (2834) 000000000
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1397332 Schaefer P Price 303A College Road East
Princeton NJ 08540
President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock. $.001 Par Value Per Share Acquisiton 2011-10-03 40,000 $1.50 806,564 No 4 M Direct
Common Stock, $.001 Par Value Per Share Disposition 2011-10-03 40,000 $79.33 766,564 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2011-10-03 40,000 $0.00 40,000 $1.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
371,915 2014-08-10 No 4 M Direct
  1. This transaction is the result of standing instructions set forth in a Rule 10b5-1 plan previously established by filer.
  2. This number reflects a correction of 2 shares from Mr. Price's prior Form 4.
  3. Represents the weighted average sales price for price increments ranging from $77.71 to $80.56.
  4. The Reporting Person undertakes to provide, upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions reported on this Form 4.
  5. The options were granted on August 10, 2004. 25% were vested on the one-year anniversary of the grant and 6.25% became vested quarterly thereafter.
  6. Following this transaction, Mr. Price has 1,246,597.34 options remaining in total from all grants, including the 371,914.66 options reported above.